XVIVO
Manufacturing · Sweden · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Gemenskapens Gata 9, Moelndal, Vaestra G...Phone Number
+46 317882150Website
www.xvivogroup.comRevenue
$87.4 MillionStock Symbol
XVIVOIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About XVIVO
XVIVO Perfusion is a medical technology company specializing in the development and manufacturing of advanced organ preservation solutions and perfusion systems. The company focuses on creating innovative technologies that extend the viability and assess the quality of organs outside the body, primarily for transplantation purposes. XVIVO's product portfolio includes specialized solutions for preserving lungs, hearts, livers, and kidneys, utilizing both static cold storage and machine perfusion techniques. The company serves transplant centers, hospitals, and organ procurement organizations worldwide, providing critical tools that help improve transplant outcomes and potentially increase the number of organs available for transplantation. With a commitment to advancing the field of organ transplantation, XVIVO combines scientific research with clinical expertise to address one of healthcare's most challenging areasextending the window of opportunity for successful organ transplants andRead more
XVIVO Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is XVIVO your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if XVIVO has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at XVIVO
Click to see if XVIVO had a recent Job posting/layoffs
Earning: See what the market has to say on XVIVO recently announced quarterly report
Funding: Get notified immidiatlly once XVIVO has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
XVIVO, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when XVIVO launches new products
Check out if XVIVO is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined XVIVO as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
XVIVO is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
XVIVO is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about XVIVO.
XVIVO Tech Stack
A closer look at the technologies used by XVIVO
See more technologies
Most Recent Scoops
Project
XVIVO has reported that its Liver Assist has been granted Breakthrough Device designation by the FDA, with an approved IDE and CMS funding in place, while regulatory activities were temporarily paused to investigate alternative regulatory routes, and preparation is underway for an FDA Q-Sub meeting to determine the regulatory pathway, with next steps to be communicated in the Q3 report or earlier if warranted.
Medical Research, Healthcare Technology
Hiring Plans
XVIVO has announced plans to hire approximately 10 to 13 additional commercial headcounts in the US ahead of a Heart product launch, encompassing roles in sales, customer support, technical support, and clinical training and support, with scaling in Europe already underway and US scaling expected to begin during the following year.
Hiring Plans, Product Launch, Training, Sales, Customer Success
Project
XVIVO has reported that its US heart trial was fully enrolled in record time, achieving a severe PGD rate of only 7.9%, with finalization of the FDA submission underway and the team expected to submit the filing to the FDA during Q3 2026, pending validation and production data.
Product Development, Compliance, Medical Research, Clinical Operations
Project
XVIVO has reported results from the first randomized controlled trial with a superior endpoint in heart transplantation in Europe using the Heart Assist, demonstrating a reduction of severe primary graft dysfunction (PGD) by 76% (5% in the XVIVO group versus 20% in the control group) and an additional 6 lives saved per approximately 100 patients, establishing a clinical link between preservation method, severe PGD reduction, and reduced one-year mortality.
Product Launch
Project
Product Launch, Medical Research
XVIVO News & Media
Xvivo Perfusion AB (publ) (XVIPY) Q1 2026 Earnings Call Transcript
Xvivo Perfusion AB (publ) (XVIPY) Q1 2026 Earnings Call April 24, 2026 8:00 AM EDTCompany ParticipantsChristoffer Rosenblad - Chief Executive...First use of new technology makes marginal lung donation viable for lifesaving transplant in Indiana
At Indiana Donor Network, functionality of donated lungs initially rejected for transplantation was improved, resulting in a lifesaving transplant. INDIANAPOLIS, IN, UNITED STATES, March 3, 2026 /EINPresswire.com/ -- On Jan. 29, 2026, an Indiana man’s …Xvivo Perfusion AB (publ) (XVIPY) Q4 2025 Earnings Call Transcript
Xvivo Perfusion AB (publ) (XVIPY) Q4 2025 Earnings Call January 27, 2026 8:00 AM ESTCompany ParticipantsChristoffer Rosenblad - Chief Executive...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding XVIVO
Sign Up For FreeTo access detailed company insights
XVIVO Perfusion is a medical technology company specializing in the development and manufacturing of advanced organ preservation solutions and perfusion systems. The company focuses on creating innovative technologies that extend the viability and assess the quality of organs outside the body, primarily for transplantation purposes. XVIVO's product... Read More
